Page 390 - 20dynamics of cancer
P. 390

SUBJECT INDEX                                               375

                                renewal, 77, 261–63, 265         melanocytes, 263
                                See also skin                    renewal, 262–63, 292–94
                              epigenetic change, 191, 193, 213,  heart disease, 204, 205, 207
                                 220, 306                      hematopoiesis, 255, 265
                                DNA methylation, 45–49, 71, 79–  heritability, see genetic predisposi-
                                 80, 199–200, 288–94, 297–300,    tion
                                 304                           heterogeneity and incidence, 175–78,
                                histone modification, 71, 80, 286,  310
                                 304                             developmental, 272–80
                              epithelial tissue                  environmental, 129–35
                                cancer incidence, 252–53         genetic, continuous, 129–35
                                See also colorectal epithelium,  genetic, discrete, 120–29
                                 epidermis                     histones, see epigenetic change
                              esophageal cancer, 29–32, 170, 300,
                                 303–4, 307, 321, 322, 331     incidence and acceleration curves,
                              evolutionary forces, see population  plots of
                                 genetics                        bladder, 317, 318, 329
                                                                 bone, 24, 25
                              field cancerization, see mosaicism  brain, 323, 324, 332
                              fitting models                      breast, 218, 315, 316
                                parameters, instability of esti-  cervix, 325, 326
                                 mates, 88, 146, 237             colorectum, 91, 217, 226, 317,
                                parameters, too many, 87          318, 328
                                                                 esophagus, 321, 322, 331
                              gatekeeper genes, 71               Hodgkin’s lymphoma, 323, 324,
                              genetic predisposition, 25–29, 143–  333
                                 64, 213–50                      kidney, 321, 322, 332
                                common versus rare variants,     larynx, 321, 322, 331
                                 243–50                          leukemia, 319, 320, 330
                                and incidence, 214–33            liver, 24, 25, 325, 326, 333
                                Mendelian variants, 26, 65–68,   lung, 30, 169, 182, 183, 315, 316,
                                 70, 89, 144–54, 161, 162, 217,   328
                                 227–29, 232, 238–42, 291        melanoma, 319, 320, 330
                                natural selection and variation,  myeloma, 323, 324, 332
                                 234–42                          neuroblastoma, 24
                                polygenic (quantitative) variation,  non-Hodgkin’s lymphoma, 319,
                                 129–35, 160–64, 228, 243–50      320, 330
                              genetic variation, see genetic predis-  oral-pharyngeal, 317, 318, 329
                                 position                        ovary, 321, 322
                              germline mutations, see genetic    pancreas, 317, 318
                                 predisposition                  prostate, 315, 316
                              glomuvenous malformations, 306–7   retinoblastoma, 24, 25, 27, 145,
                                See also mosaicism                149, 151
                              Gompertz model, 136–39             stomach, 319, 320, 331
                                                                 testis, 24, 25
                              hair follicle                      thyroid, 323, 324, 333
                                bulge stem cells, 262, 292–94    Wilms’ tumor, 24, 25
   385   386   387   388   389   390   391   392   393   394   395